Method for preparing brivaracetam by enzyme method

Through the catalysis of ene reductase and coenzyme, the problem of consuming a lot of reagents and solvents in the preparation of existing bovacetam is solved, and the efficient and green bovacetam preparation is achieved, achieving high conversion rate and high purity, suitable for industrialization Production.

CN119061090APending Publication Date: 2024-12-03SYNCOZYMES SHANGHAI

Patent Information

Application Number
CN202310618057.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-30
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing bovacetam preparation method consumes a large amount of resolving reagents and solvents, has poor atomic economy and high production costs, making it difficult to achieve simple, efficient and green preparation.

Method used

Compound II is converted to bovacetam using ene reductase and coenzyme catalyzed method, using ene reductase from genetically engineered E. coli or yeast to combine potassium phosphate buffer and specific coenzymes through selective catalytic reactions. , achieve efficient preparation.

Benefits of technology

It achieves high conversion rate (>98%) and high chiral purity (≥99%) of bovacetam, which is simple to operate, has high atomic economy, and is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004254535740000011
    Figure BDA0004254535740000011
  • Figure BDA0004254535740000021
    Figure BDA0004254535740000021
  • Figure BDA0004254535740000022
    Figure BDA0004254535740000022
Patent Text Reader

Abstract

The invention discloses a method for preparing brivaracetam by an enzyme method. According to the invention, a compound II is used as a substrate and is converted into brivaracetam under the catalytic action of alkene reductase and coenzyme. According to the method, a chiral resolution process is avoided, and the atom economy is high.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field:

[0001] The invention belongs to the technical field of biocatalysis, and particularly relates to a method for preparing brivaracetam by an enzymatic method. Background technology:

[0002] Brivaracetam is an anti-epileptic drug developed by UCB of Belgium, with a structure shown in Formula A. In February 2016, Brivaracetam was approved by the FDA for marketing in the United States for the treatment of partial-onset epilepsy in patients aged 16 years and above, and as an adjuvant treatment with or without secondary systemic seizures.

[0003]

[0004] Currently, the synthesis of brivaracetam is mainly prepared by splitting diastereoisomers through chiral chromatography or chiral reagents.

[0005] The preparation method of brivaracetam disclosed by the original UCB company in patent CN1882535 is shown in Scheme 1. First, an unsaturated lactam intermediate II is prepared, and then a mixture of brivaracetam diastereoisomers is obtained by Pd / C hydrogenation reduction. Finally, chiral column chromatography is used for separation to obtain brivaracetam with high purity.

[0006] On this basis, many improved methods have emerged. Patent WO2007065634A1 replaces the Pd / C catalyst with the precious metal catalyst RuCl 3 Patent CN106748950A uses an equivalent amount of chiral phenylethylamine as a resolution agent to prepare brivaracetam. However, these methods are all diastereoisomer resolution processes, which not only consume a large amount of resolution agents and solvents, but also have poor atom economy and high production costs.

[0007]

[0008] Therefore, it is of great significance to develop a simple, efficient, green, and atom-economical method for preparing brivaracetam. Summary of the invention:

[0009] The purpose of the present invention is to provide a method for preparing brivaracetam which is simple to operate and easy to industrialize in view of the deficiencies in the prior art.

[0010] The technical solution adopted by the present invention is as follows:

[0011]

[0012] The present invention provides a method for preparing brivaracetam, which specifically comprises the following steps: compound II is converted into compound I under the catalysis of olefin reductase and coenzyme.

[0013] Furthermore, the concentration of the compound II is 20-25 g / L.

[0014] Furthermore, the olefin reductase is derived from Saccharomyces cerevisiae.

[0015] Furthermore, the ene reductase is from the ene reductase (ES-ERED-101 to ES-ERED-146) sold by Shangke Biopharmaceuticals (Shanghai) Co., Ltd.

[0016] Furthermore, the ene reductase is obtained by fermentation of genetically engineered bacteria, and the genetically engineered bacteria are genetically engineered Escherichia coli or yeast.

[0017] Furthermore, the ene reductase participates in the catalytic reaction in the form of ene reductase enzyme powder, ene reductase enzyme solution, cells containing ene reductase, etc.

[0018] Furthermore, the concentration of the olefin reductase powder is 2-5 g / L.

[0019] Furthermore, the catalytic reaction time is 12 to 48 hours, preferably 18 to 24 hours.

[0020] Furthermore, coenzymes can be added to the reaction system to promote the reaction. When cells containing olefin reductase are used, the cells contain a small amount of coenzymes, and the coenzymes may not be added at this time. In some cases, the prepared olefin reductase enzyme powder also contains a small amount of coenzymes, and the coenzymes may not be added at this time. However, coenzymes can also be added to the reaction system to further promote the reaction. When coenzymes are added to the reaction system to promote the reaction, the coenzymes are selected from NAD + , NADH, NADP + , NADPH or a combination thereof, preferably NADP + .

[0021] Furthermore, the concentration of the added coenzyme is 0.01 to 0.1 g / L, preferably 0.01 to 0.05 g / L.

[0022] Furthermore, the coenzymes used in this technical solution are all selected from the coenzyme products sold by Shangke Biopharmaceuticals (Shanghai) Co., Ltd.

[0023] Furthermore, a buffer needs to be added in the reaction, and the buffer is selected from potassium phosphate buffer.

[0024] Furthermore, the preparation method of the compound II is selected from the preparation method disclosed in patent US10421717, as shown in Scheme 3. The method mainly uses n-valeraldehyde and glyoxylic acid as starting materials to cyclize to obtain compound V, and then reacts with (S)-2-aminobutanamide to obtain pyrrolidinobutanamide compound II

[0025]

[0026] The beneficial effect of the present invention is that the present invention provides a new method for preparing brivaracetam. The present invention selectively converts compound II into brivaracetam through ene reductase, the conversion substrate concentration can reach 25g / L, the conversion rate is >98%, the chiral purity is ≥99%, the operation is simple, the atom economy is high, and it can be used for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] none DETAILED DESCRIPTION

[0028] The technical content of the present invention is further described below in conjunction with specific embodiments, the purpose of which is to provide a better understanding of the content of the present invention, but the protection scope of the present invention is not limited thereto.

[0029] Example 1 Preparation of Compound V

[0030] Add morpholine (25.87g, 0.297mol, 1.09eq) and n-heptane 80mL to a three-necked flask, and slowly drop glyoxylic acid (50w% dissolved in water) (20g, 0.27mol, 1.0eq) in an ice-water bath. After the addition is complete, warm to room temperature, stir for 1h, then add n-valeraldehyde (24.42g, 0.286mol, 1.06eq), and after the addition is complete, warm to 43°C, stir for 20h to complete the reaction. Slowly add 40mL of 37% concentrated hydrochloric acid to the mixture and continue stirring for 2h. Remove n-heptane by rotary evaporation, then wash twice with n-heptane, leaving the aqueous phase. Add diisopropyl ether to the aqueous phase, remove the organic phase, extract the aqueous phase twice with diisopropyl ether, combine the organic phases, wash with brine, and remove the solvent to obtain 41.08g of crude product.

[0031] Example 2 Preparation of Compound II

[0032] Add (S)-2-aminobutyramide (8.37 g, 0.08 mol, 1.14 eq), compound V (10 g, 0.07 mol, 1.0 eq), and 72 mL of isopropanol to a 250 mL three-necked flask, raise the temperature to 40 °C, and react for 1 h before lowering the temperature to 5 °C. 4(1.77g, 0.047mol, 0.65eq) was dissolved in 5mL of water and slowly added dropwise to the reaction system. After the addition was complete, it was stirred for 1h. Acetone (10.88g, 0.187mol, 2.6eq) was added. After the addition was complete, it was stirred for 5 minutes and the solid was filtered out. 2mL of acetic acid was added dropwise to the filtrate to adjust the pH to 7-8. The temperature was raised to 50℃ and the reaction was completed for 16h. Then the temperature was lowered to room temperature and the solvent was removed by concentration under reduced pressure. After the concentration was completed, the product was extracted, filtered and concentrated to obtain 17.51g.

[0033] Example 3 Preparation of Compound I

[0034] Add ene reductase powder (150 mg, ES-ERED-135 of Shangke Biopharmaceutical (Shanghai) Co., Ltd.), NADP 0.75 mg, glucose 1.2 g, deionized water 20 mL, glucose dehydrogenase (0.4 mg, ES-GDH-110 of Shangke Biopharmaceutical (Shanghai) Co., Ltd.) and 0.1M pH7.5 potassium phosphate buffer 50 mL to a 50 mL three-necked flask, and stir to dissolve. Dissolve compound II (1.5 g, 0.0071 mol, 1.0 eq) in 1 mL of water and slowly dropwise add to the system, stir at 30 ° C for 24 h, take a sample for HPLC detection, and the conversion rate is 98%. The reaction is complete, cool to room temperature, filter with diatomaceous earth, extract the filtrate with ethyl acetate, combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate under reduced pressure to remove the solvent to obtain 0.8 g of crude product, which is recrystallized from isopropyl acetate to obtain 0.7 g of pure Bu Waxitan, with a chiral purity of ≥99%.

[0035] Example 4 Preparation of Compound I

[0036] Add ene reductase powder (260 mg, ES-ERED-127 of Shangke Biopharmaceutical (Shanghai) Co., Ltd.), NADP 3.75 mg, glucose 1.2 g, deionized water 20 mL, glucose dehydrogenase (1.85 mg, ES-GDH-110 of Shangke Biopharmaceutical (Shanghai) Co., Ltd.) and 0.1M pH7.5 potassium phosphate buffer 50 mL to a 50 mL three-necked flask, and stir to dissolve. Dissolve compound II (1.9 mg, 0.009 mol, 1.0 eq) in 1 mL of water and slowly dropwise add to the system, stir at 30 ° C for 24 h, take a sample for HPLC detection, and the conversion rate is 94%. The reaction is complete, cool to room temperature, filter with diatomaceous earth, extract the filtrate with ethyl acetate, combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate under reduced pressure to remove the solvent to obtain 0.72 g of crude product, which is recrystallized from isopropyl acetate to obtain 0.58 g of pure Bu Waxitan, with a chiral purity of ≥98%.

[0037] Example 5 Preparation of Compound I

[0038] Add ene reductase enzyme solution (375 mg, ES-ERED-135 of Shangke Biopharmaceuticals (Shanghai) Co., Ltd.), NAD 7.5 mg, glucose 1.2 g, deionized water 20 mL, glucose dehydrogenase (3.75 mg, ES-GDH-110 of Shangke Biopharmaceuticals (Shanghai) Co., Ltd.) and 0.1M pH 7.5 potassium phosphate buffer 50 mL to a 50 mL three-necked flask, and stir to dissolve. Dissolve compound II (3.75 g, 0.0178 mol, 1.0 eq) in 1 mL of water and slowly dropwise add to the system, stir at 30 ° C for 24 h, take a sample for HPLC detection, and the conversion rate is 88%. The reaction is complete, cool to room temperature, filter with diatomaceous earth, extract the filtrate with ethyl acetate, combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate under reduced pressure to remove the solvent to obtain 0.58 g of crude product, which is recrystallized from isopropyl acetate to obtain 0.4 g of pure Bu Waxitan, with a chiral purity of ≥98%.

Claims

1. An enzymatic preparation method of brivaracetam, characterized in that: Compound II is converted into compound I under the catalysis of olefin reductase and coenzyme. The reaction equation is shown below:

2. The preparation method according to claim 1, characterized in that The olefin reductase is derived from Saccharomyces cerevisiae.

3. The preparation method according to claim 1, characterized in that: The coenzyme is selected from NAD + , NADH, NADP + , NADPH or a combination thereof.

4. The preparation method according to claim 1, characterized in that: In the preparation method, glucose and glucose dehydrogenase are added for regeneration of the coenzyme.

Citation Information

Patent Citations

  • Brivaracetam and preparation method of intermediate thereof

    CN106748950A

  • Process for preparing brivaracetam

    US10421717B2

  • 3-carboxy- 2-oxo-1 -pyrrolidine derivatives and their uses

    WO2007065634A1

Cited By

  • Alkene reductase mutant and application thereof in preparation of brivaracetam intermediate

    CN119876055A